Antibody–drug conjugates (ADCs) are specifically designed with the objective of delivering antineoplastic agents in the most precise and selectively targeted way, increasing the antitumoral efficacy while minimizing toxicity to normal tissues. Read More…
The investigation concluded that gut microbiome pathways associated with bacterial invasion of epithelial cells may predict response to nivolumab treatment in these patients. The trial also found that gastric cancer patients who responded to nivolumab treatment had a more diverse gut microbiome than did their counterparts who did not respond to Read more…
Findings from the randomised phase II NEOSTAR study indicate that neoadjuvant treatment with nivolumab plus ipilimumab enhances pathologic responses, tumour immune infiltrates and immunologic memory in patients with operable non-small cell lung cancer (NSCLC). Tina Cascone of the Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center Read more…
The FDA granted approval for an expanded indication for the poly(adenosine diphosphate–ribose) polymerase inhibitor niraparib (Zejula, GlaxoSmithKline): treatment of patients with advanced ovarian, fallopian tube or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive Read more…
The FDA approved new indications for olaparib (Lynparza, AstraZeneca) and bevacizumab-awwb (Mvasi, Amgen) to be used in combination for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Read More…
The FDA approved cemiplimab-rwlc (Libtayo, Regeneron/Sanofi) for the first-line treatment of patients with metastatic or locally advanced or metastatic non-small cell lung cancer (NSCLC) that is unresectable and not amenable to definitive chemoradiation whose tumors have high PD-L1 expression and no EGFR, ALK or ROS1 aberrations. Read More…
A new study supports exhausting noninvasive methods to diagnose hepatocellular carcinoma (HCC) before attempting biopsy. In an analysis of data from the National Cancer Database, overall survival (OS) was lower in HCC patients who underwent preoperative tissue diagnosis compared with those with a clinical diagnosis. Read More…
The FDA granted accelerated approval to melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with dexamethasone for adults with relapsed or refractory multiple myeloma (MM) who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one Read more…
Increasing time to surgery beyond four weeks is a modifiable risk factor for adverse oncologic outcomes after neoadjuvant chemotherapy for breast cancer, according to a new study presented at the 2020 annual meeting of the Society of Surgical Oncology (SSO), held virtually (abstract 12). Read More…
In men with metastatic castration-resistant prostate cancer (mCRPC) and mutations in genes associated with homologous recombination repair (HRR), such as BRCA1 or BRCA2, olaparib improves overall survival (OS), according to results of the open-label, phase 3 PROfound trial. Read More…